Global Expansion And Decentralized Testing Will Unlock Future Potential

Published
21 Mar 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$43.14
39.9% undervalued intrinsic discount
14 Aug
US$25.93
Loading
1Y
-41.0%
7D
8.4%

Author's Valuation

US$43.1

39.9% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 Aug 25
Fair value Decreased 8.48%

The consensus analyst price target for QuidelOrtho has been revised downward, primarily reflecting a sharp deterioration in profitability—evidenced by a collapse in net profit margin and a spike in the future P/E ratio—with fair value lowered from $47.14 to $43.57. What's in the News QuidelOrtho reiterated its full year 2025 earnings guidance, with expected revenues between $2.60 billion and $2.81 billion.

Shared on01 May 25
Fair value Decreased 1.91%

Shared on24 Apr 25
Fair value Decreased 3.65%

AnalystConsensusTarget has decreased profit margin from 12.9% to 2.6% and increased future PE multiple from 12.1x to 59.0x.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.28%

AnalystConsensusTarget has increased revenue growth from 1.9% to 2.1%.

Shared on02 Apr 25
Fair value Decreased 0.91%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 7.08%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.